Abstract
Background This study was aimed to develop a sensitive and rapid assay for the determination of glial fibrillary acidic protein (GFAP) in serum and to evaluate the clinical applicability in serum samples from patients with acute stroke. Methods The two-site chemiluminometric immunoassay, intended to use in a near-patient setting with a single incubation step (20 min), was used to measure serum samples from healthy blood donors and from patients with brain injury and correlated to serum S100B levels. Results The GFAP assay covered a concentration range up to 18 μg/L with an analytical sensitivity of 0.014 μg/L. The intra-assay precision was 3.5% at 1.55 μg/L ( n = 20) and 4.1% at 0.39 μg/L ( n = 20). The inter-assay precision was 3.8% at 9.1 μg/L ( n = 10) and 10.3 % at 0.21 μg/L ( n = 9). Normal controls ( n = 46) showed non-detectable GFAP with a 99% upper limit of < 0.04 μg/L. GFAP values were associated with progression and severity of the illness in acute stroke patients. Conclusions We have developed an improved assay for the measurement of GFAP levels in serum. Serum GFAP is a potential marker for prognosis and outcome in patients with central nervous system disorders.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
